Vanda Pharmaceuticals (VNDA) Tops Q4 Views
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
EPS Growth %: -30.4%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of $0.36, $0.35 better than the analyst estimate of $0.01. Revenue for the quarter came in at $53.04 million versus the consensus estimate of $51.7 million.
GUIDANCE:
2019 Financial Guidance
Vanda expects to achieve the following financial objectives in 2019:
Full Year 2019 Guidance | |
Combined net product sales from both HETLIOZ® and Fanapt® | $215 to $225 million |
HETLIOZ® net product sales | $137 to $143 million |
Fanapt® net product sales | $78 to $82 million |
Year-end 2019 Cash | Greater than $260 million |
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Rivian raises 2026 delivery outlook after Q2 results top guidance
- Pembina joins proposed 1M bbl/day Alberta-to-coast pipeline plan
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
